Selected Publications from BMT Fellowship Alumni
Muffly LS, Lee CL. Coordination of care in survivorship after treatment of hematological malignancies-The journey is not over yet. Current Hematologic Malignancy Report, 2017; epub
Veeraputhiran M, Yang L, Sundaram V, Arai S, Lowsky R, Miklos D, Meyer E, Muffly L, Negrin R, Rezvani A, Shizuru J, Weng W-K, Johnston L. Validation of the hematopoietic cell transplantation-specific comorbidity index in nonmyeloablative allogeneic stem cell transplanatation. Biology of Blood and Marrow Transplantation, 2017; ePub
Lee CJ, Shiraz P, Muffly L, Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Leukemia & Lymphoma, 2017, 58(3):516-527
Muffly L, Lichtensztajn, D, Shiraz P, Renata Abrahao R, McNeer J, Stock W, Keegan T, Gomez SL, Adoption of Pediatric-Inspired Acute Lymphoblastic Leukemia Regimens by Adult Oncologists Treating Adolescents and Young Adults: A Population-Based Study. Cancer, 2017, 123(1):122-130
Arora M, Cutler CS, Jagasia MH, Pidala J, Chai X, Martin PJ, Flowers ME, Inamoto Y, Chen GL, Wood WA, Khera N, Palmer J, Duong H, Arai S, Mayer S, Pusic I, Lee SJ. Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22(3):449-455
Arai S, Pidala J, Pusic I, Chai X, Jaglowski S, Khera N, Palmer J, Chen GL, Jagasia MH, Mayer SA, Wood WA, Green M, Hyun TS, Inamoto Y, Storer BE, Miklos DB, Shulman HM, Martin PJ, Sarantopoulos S, Lee SJ, Flowers ME. A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. Clinical Cancer Research, 2016, 22(2):319-327
Rezvani AR, Kanate AS, Efron B, Chhabra S, Kohrt HE, Shizuru JA, Laport GG, Miklos DB, Benjamin JE, Johnston LJ, Arai S, Weng WK, Negrin RS, Strober S, Lowsky R. Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning. Bone Marrow Transplantation, 2015, 50(10):1286-1292
Logan AC, Wang Z, Alimoghaddam K, Wong, RM, Lai T, Negrin RS, Grumet C, Logan BR, Zhang M, Spellman SR, Lee SJ, Miklos DB. ABO Mismatch Is Associated with Increased Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21(4):746-754
Logan AC, Vashi N, Faham M, Carlton V, Kong K, Buno I, Zheng J, Moorhead M, Klinger M, Zhang B, Waqar A, Zehnder JL, Miklos DB. Immunoglobulin and T Cell Receptor Gene High-Throughput Sequencing Quantifies Minimal Residual Disease in Acute Lymphoblastic Leukemia and Predicts Post-Transplantation Relapse and Survival. Biology of Blood and Marrow Transplantation, 2014, 20(9):1307-1313
Benjamin J, Chhabra S, Kohrt HE, Lavori P, Laport GG, Arai S, Johnston L, Miklos DB, Shizuru JA, Weng WK, Negrin RS, Lowsky R. Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms. Biology of Blood and Marrow Transplantation, 2014, 20(6):837-843
Logan AC, Zhang B, Narasimhan B, Carlton V, Zheng J, Moorhead M, Krampf MR, Jones CD, Waqar AN, Faham M, Zehnder JL, Miklos DB. Minimal residual disease quantification using consensus primers and high- throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. Leukemia, 2013, 27(8):1659-1665
Arai S, Sahaf B, Narasimhan B, Chen GL, Jones CD, Lowsky R, Shizuru JA, Johnston LJ, Laport GG, Weng WK, Benjamin JE, Schaenman J, Brown J, Ramirez J, Zehnder JL, Negrin RS, Miklos DB. Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood, 2012, 119(25):6145-54
Chen AI, Negrin RS, McMillan A, Shizuru JA, JOHNSTON LJ, Lowsky R, Miklos DB, Arai S, Weng W, Laport GG, Stockerl-Goldstein K. Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma. Bone Marrow Transplantation, 2012, 47(4):516-521
Chen GL, Arai S, Flowers ME, Otani JM, Qiu J, Cheng EC, McMillan A, Johnston LJ, Shizuru JA, Miklos DB. A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. Blood, 2011, 118(15):4070-8
Logan AC, Gao H, Wang C, Sahaf B, Jones CD, Marshall EL, Buno I, Armstrong R, Fire AZ, Weinberg KI, Mindrinos M, Zehnder JL, Boyd SD, Xiao W, Davis RW, Miklos DB. High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108(52):21194-21199
Naik S, Wong R, Arai S, Brown J, Laport G, Lowsky R, Miklos D, Shizuru J, Blume K, Negrin R, Johnston L. Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. Bone Marrow Transplantation, 2011, 46(2):192-199
Benjamin JE, Chen GL, Cao TM, Cao PD, Wong RM, Sheehan K, Shizuru JA, Johnston LJ, Negrin RS, Lowsky R, Laport GG. Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure. Bone Marrow Transplantation, 2009, 45(2):303-309
Kohrt HE, Turnbull BB, Heydari K, Shizuru JA, Laport GG, Miklos DB, Johnston LJ, Arai S, Weng W, Hoppe RT, Lavori PW, Blume KG, Negrin RS, Strober S, Lowsky R. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. BLOOD, 2009, 114(5):1099-1109
Cao TM, Shizuru JA, Wong RM, Sheehan, K., Laport, GG, Stockerl-Goldstein KE, Johnston LJ, Stuart MJ, Grumet FC, Negrin RS, Lowsky R. Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8(+) T-cell dose. BLOOD, 2005, 105(6):2300-2306
Cao TM, Wong RM, Sheehan K, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Shizuru JA, Negrin RS, Lowsky R. CD34, CD49 and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. Experimental Hematology, 2005, 33(3):279-285